Hepion pharmaceuticals and fibrofind announce anti-cancer activity of crv431 in a nonclinical liver cancer study

Edison, n.j., nov. 16, 2021 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and other liver diseases, today announced the results of a nonclinical research study showing that crv431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. additionally, crv431 was as effective at decreasing tumor burden as an anti-pd1 antibody immune checkpoint inhibitor, pd1 antibody, and produced more beneficial changes in tumor infiltrating cells compared to anti-pd1 antibody treatment.
HEPA Ratings Summary
HEPA Quant Ranking